The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies
- 14 December 2010
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 63 (4), 341-351
- https://doi.org/10.1016/j.phrs.2010.12.002
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of TauopathyJournal of Neuroscience, 2010
- Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathiesNature Reviews Drug Discovery, 2009
- Design, Synthesis, and Biological Evaluation of New-Generation TaxoidsJournal of Medicinal Chemistry, 2008
- Mice Lacking Histone Deacetylase 6 Have Hyperacetylated Tubulin but Are Viable and Develop NormallyMolecular and Cellular Biology, 2008
- Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxelInvestigational New Drugs, 2007
- Paclitaxel C-10 carbamates: Potential candidates for the treatment of neurodegenerative tauopathiesBioorganic & Medicinal Chemistry Letters, 2007
- Tau phosphorylation and aggregation in Alzheimer's disease pathologyFEBS Letters, 2006
- Evaluation of the MDR-MDCK cell line as a permeability screen for the blood–brain barrierInternational Journal of Pharmaceutics, 2004
- Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and ratsBritish Journal of Pharmacology, 2003
- Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule bindingNeuron, 1993